| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Prescriptions | 54 | 2015 | 1637 | 3.410 |
Why?
|
| Medicare Part D | 18 | 2021 | 328 | 3.330 |
Why?
|
| Deductibles and Coinsurance | 29 | 2022 | 316 | 2.690 |
Why?
|
| Insurance, Pharmaceutical Services | 25 | 2013 | 336 | 2.440 |
Why?
|
| Drug Utilization | 58 | 2013 | 1183 | 2.430 |
Why?
|
| Medicaid | 47 | 2017 | 2737 | 2.330 |
Why?
|
| Health Maintenance Organizations | 32 | 2016 | 642 | 2.050 |
Why?
|
| Drug Utilization Review | 14 | 2011 | 245 | 2.040 |
Why?
|
| Comparative Effectiveness Research | 5 | 2019 | 680 | 1.890 |
Why?
|
| Prescription Fees | 10 | 2014 | 146 | 1.800 |
Why?
|
| Drug Costs | 27 | 2021 | 1105 | 1.750 |
Why?
|
| Benzodiazepines | 13 | 2024 | 1101 | 1.700 |
Why?
|
| Antidepressive Agents | 17 | 2018 | 2838 | 1.540 |
Why?
|
| Mass Media | 7 | 2014 | 305 | 1.520 |
Why?
|
| Cost Sharing | 20 | 2021 | 407 | 1.450 |
Why?
|
| Treatment Refusal | 8 | 2013 | 421 | 1.350 |
Why?
|
| United States Food and Drug Administration | 10 | 2018 | 1584 | 1.310 |
Why?
|
| Financing, Personal | 12 | 2020 | 308 | 1.270 |
Why?
|
| Drug Therapy | 13 | 2008 | 497 | 1.270 |
Why?
|
| Medicare | 27 | 2021 | 6566 | 1.210 |
Why?
|
| Medication Adherence | 10 | 2021 | 2063 | 1.150 |
Why?
|
| Product Surveillance, Postmarketing | 6 | 2014 | 430 | 1.140 |
Why?
|
| Health Services Research | 16 | 2016 | 1836 | 1.040 |
Why?
|
| Insurance Coverage | 15 | 2018 | 1900 | 1.000 |
Why?
|
| Education, Medical, Continuing | 18 | 2007 | 840 | 1.000 |
Why?
|
| Patient Compliance | 18 | 2010 | 2684 | 0.980 |
Why?
|
| Health Policy | 22 | 2018 | 2661 | 0.970 |
Why?
|
| Clinical Pharmacy Information Systems | 6 | 2006 | 103 | 0.960 |
Why?
|
| Bipolar Disorder | 11 | 2022 | 5027 | 0.950 |
Why?
|
| Reimbursement, Incentive | 7 | 2016 | 540 | 0.940 |
Why?
|
| Research Design | 18 | 2018 | 5984 | 0.910 |
Why?
|
| Antipsychotic Agents | 10 | 2022 | 3057 | 0.880 |
Why?
|
| Disabled Persons | 8 | 2021 | 1212 | 0.850 |
Why?
|
| Health Services | 5 | 2013 | 758 | 0.780 |
Why?
|
| Psychotropic Drugs | 9 | 2015 | 894 | 0.770 |
Why?
|
| State Health Plans | 10 | 2013 | 216 | 0.740 |
Why?
|
| United States | 113 | 2021 | 69872 | 0.730 |
Why?
|
| Suicide | 3 | 2014 | 1474 | 0.700 |
Why?
|
| Reimbursement Mechanisms | 8 | 2011 | 670 | 0.680 |
Why?
|
| Quality Assurance, Health Care | 10 | 2016 | 2212 | 0.660 |
Why?
|
| Poverty | 10 | 2020 | 2660 | 0.630 |
Why?
|
| Schizophrenia | 8 | 2015 | 6882 | 0.610 |
Why?
|
| Leukotriene Antagonists | 2 | 2015 | 127 | 0.610 |
Why?
|
| Electronic Health Records | 5 | 2016 | 4468 | 0.600 |
Why?
|
| Health Expenditures | 17 | 2022 | 2349 | 0.580 |
Why?
|
| Reminder Systems | 4 | 2009 | 371 | 0.580 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2008 | 1240 | 0.570 |
Why?
|
| Fees, Pharmaceutical | 5 | 2011 | 64 | 0.570 |
Why?
|
| Legislation, Drug | 5 | 2010 | 206 | 0.560 |
Why?
|
| Quality of Health Care | 15 | 2011 | 4369 | 0.560 |
Why?
|
| Drug Labeling | 7 | 2015 | 233 | 0.540 |
Why?
|
| Humans | 270 | 2024 | 744366 | 0.540 |
Why?
|
| Gatekeeping | 4 | 2010 | 45 | 0.530 |
Why?
|
| Insurance, Health | 13 | 2020 | 2494 | 0.520 |
Why?
|
| Antihypertensive Agents | 7 | 2017 | 2047 | 0.520 |
Why?
|
| Ambulatory Care | 8 | 2017 | 2708 | 0.520 |
Why?
|
| Anti-Anxiety Agents | 4 | 2010 | 390 | 0.510 |
Why?
|
| Medical Indigency | 4 | 2011 | 64 | 0.500 |
Why?
|
| Guideline Adherence | 16 | 2014 | 2265 | 0.490 |
Why?
|
| Formularies as Topic | 7 | 2009 | 91 | 0.490 |
Why?
|
| Anticonvulsants | 4 | 2012 | 1916 | 0.480 |
Why?
|
| Histamine H2 Antagonists | 3 | 2005 | 165 | 0.470 |
Why?
|
| Aged | 105 | 2021 | 163288 | 0.460 |
Why?
|
| Mental Disorders | 9 | 2016 | 6598 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2016 | 9955 | 0.460 |
Why?
|
| Myocardial Infarction | 15 | 2008 | 11718 | 0.460 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2015 | 346 | 0.450 |
Why?
|
| Female | 153 | 2021 | 380193 | 0.450 |
Why?
|
| Male | 144 | 2021 | 350115 | 0.450 |
Why?
|
| Marketing | 2 | 2012 | 212 | 0.440 |
Why?
|
| Community Mental Health Centers | 2 | 2011 | 102 | 0.430 |
Why?
|
| Middle Aged | 103 | 2021 | 213390 | 0.430 |
Why?
|
| Clinical Coding | 1 | 2014 | 171 | 0.430 |
Why?
|
| Suicide, Attempted | 3 | 2018 | 1218 | 0.420 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2015 | 536 | 0.420 |
Why?
|
| Medical Staff, Hospital | 5 | 2006 | 601 | 0.420 |
Why?
|
| Primary Health Care | 14 | 2015 | 4557 | 0.420 |
Why?
|
| Diabetes Mellitus | 13 | 2020 | 5749 | 0.420 |
Why?
|
| Medically Uninsured | 2 | 2020 | 853 | 0.410 |
Why?
|
| Chronic Disease | 13 | 2021 | 9145 | 0.410 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2012 | 141 | 0.400 |
Why?
|
| Cost of Illness | 4 | 2013 | 1860 | 0.400 |
Why?
|
| Cost Control | 17 | 2010 | 624 | 0.400 |
Why?
|
| Drug Monitoring | 2 | 2009 | 956 | 0.400 |
Why?
|
| Drug Industry | 6 | 2012 | 746 | 0.400 |
Why?
|
| Emergency Service, Hospital | 12 | 2018 | 7658 | 0.390 |
Why?
|
| Hypolipidemic Agents | 4 | 2017 | 604 | 0.390 |
Why?
|
| Child Behavior Disorders | 2 | 2016 | 807 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2007 | 1516 | 0.380 |
Why?
|
| Off-Label Use | 1 | 2012 | 169 | 0.380 |
Why?
|
| Amines | 1 | 2012 | 276 | 0.380 |
Why?
|
| Cluster Analysis | 3 | 2014 | 2715 | 0.380 |
Why?
|
| Catheter-Related Infections | 4 | 2015 | 252 | 0.380 |
Why?
|
| Medication Errors | 3 | 2006 | 798 | 0.380 |
Why?
|
| Managed Care Programs | 6 | 2008 | 950 | 0.370 |
Why?
|
| Calcium Channel Blockers | 5 | 2003 | 692 | 0.370 |
Why?
|
| Economics, Hospital | 5 | 2015 | 213 | 0.370 |
Why?
|
| Hospitalization | 13 | 2018 | 10259 | 0.360 |
Why?
|
| Medical Records | 7 | 2011 | 1413 | 0.360 |
Why?
|
| Program Evaluation | 8 | 2015 | 2488 | 0.360 |
Why?
|
| New Jersey | 11 | 2011 | 290 | 0.360 |
Why?
|
| Access to Information | 1 | 2013 | 320 | 0.350 |
Why?
|
| Emergencies | 1 | 2016 | 1170 | 0.350 |
Why?
|
| Warfarin | 4 | 2008 | 1497 | 0.350 |
Why?
|
| New Hampshire | 9 | 2010 | 172 | 0.340 |
Why?
|
| Fast Foods | 1 | 2011 | 197 | 0.340 |
Why?
|
| Polypharmacy | 4 | 2014 | 294 | 0.340 |
Why?
|
| Efficiency, Organizational | 2 | 2012 | 695 | 0.340 |
Why?
|
| Nursing Homes | 10 | 2010 | 1036 | 0.340 |
Why?
|
| Pregnadienediols | 1 | 2008 | 9 | 0.340 |
Why?
|
| Food Labeling | 1 | 2011 | 178 | 0.330 |
Why?
|
| Adult | 81 | 2021 | 214052 | 0.330 |
Why?
|
| Mental Health Services | 5 | 2016 | 1644 | 0.330 |
Why?
|
| Government Programs | 1 | 2011 | 275 | 0.330 |
Why?
|
| Health Care Costs | 10 | 2020 | 3208 | 0.330 |
Why?
|
| Benchmarking | 1 | 2015 | 1042 | 0.320 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 1405 | 0.320 |
Why?
|
| Hip Fractures | 4 | 2015 | 955 | 0.320 |
Why?
|
| Pharmaceutical Services | 2 | 2008 | 140 | 0.310 |
Why?
|
| Cross Infection | 5 | 2015 | 1417 | 0.310 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2007 | 434 | 0.310 |
Why?
|
| Socioeconomic Factors | 16 | 2016 | 7785 | 0.310 |
Why?
|
| Drug Information Services | 8 | 2012 | 51 | 0.310 |
Why?
|
| Health Benefit Plans, Employee | 3 | 2017 | 332 | 0.300 |
Why?
|
| Depressive Disorder | 4 | 2009 | 3747 | 0.300 |
Why?
|
| Internet | 2 | 2013 | 3056 | 0.290 |
Why?
|
| Drug Approval | 6 | 2014 | 742 | 0.290 |
Why?
|
| Hypoglycemic Agents | 8 | 2020 | 2873 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2015 | 1856 | 0.280 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2009 | 738 | 0.280 |
Why?
|
| Cost-Benefit Analysis | 15 | 2015 | 5388 | 0.280 |
Why?
|
| Maine | 4 | 2011 | 139 | 0.280 |
Why?
|
| Insurance Claim Review | 12 | 2016 | 720 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 1121 | 0.280 |
Why?
|
| Pediatrics | 6 | 2015 | 3475 | 0.280 |
Why?
|
| Health Status | 5 | 2015 | 4034 | 0.280 |
Why?
|
| Heart Arrest | 1 | 2016 | 1470 | 0.270 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2006 | 1164 | 0.270 |
Why?
|
| Mass Screening | 5 | 2016 | 5253 | 0.270 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 57776 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 595 | 0.270 |
Why?
|
| Patient Education as Topic | 7 | 2008 | 2278 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 3 | 2014 | 2716 | 0.270 |
Why?
|
| Prescription Drugs | 1 | 2013 | 595 | 0.270 |
Why?
|
| Thrombolytic Therapy | 6 | 2002 | 2162 | 0.270 |
Why?
|
| Adolescent | 41 | 2021 | 85779 | 0.260 |
Why?
|
| Asthma | 7 | 2016 | 6010 | 0.260 |
Why?
|
| Longitudinal Studies | 20 | 2020 | 13991 | 0.260 |
Why?
|
| Social Marketing | 1 | 2005 | 52 | 0.260 |
Why?
|
| Clinical Competence | 5 | 2006 | 4687 | 0.260 |
Why?
|
| Self Administration | 2 | 2006 | 385 | 0.260 |
Why?
|
| Medical Audit | 7 | 2009 | 467 | 0.260 |
Why?
|
| Prescriptions | 3 | 2024 | 387 | 0.260 |
Why?
|
| Anti-Infective Agents | 2 | 2006 | 974 | 0.260 |
Why?
|
| Fee-for-Service Plans | 5 | 2017 | 694 | 0.250 |
Why?
|
| Basal Ganglia Diseases | 1 | 2005 | 149 | 0.250 |
Why?
|
| Dyspepsia | 2 | 2005 | 116 | 0.250 |
Why?
|
| Depression | 5 | 2016 | 7759 | 0.240 |
Why?
|
| Health Care Reform | 4 | 2016 | 1261 | 0.240 |
Why?
|
| Antiparkinson Agents | 1 | 2005 | 184 | 0.240 |
Why?
|
| Helicobacter pylori | 2 | 2005 | 383 | 0.240 |
Why?
|
| Helicobacter Infections | 2 | 2005 | 387 | 0.240 |
Why?
|
| Medical Savings Accounts | 2 | 2022 | 32 | 0.240 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.240 |
Why?
|
| Hypertension | 7 | 2011 | 8479 | 0.230 |
Why?
|
| Dihydropyridines | 2 | 2003 | 67 | 0.230 |
Why?
|
| New York | 6 | 2007 | 886 | 0.230 |
Why?
|
| Energy Intake | 1 | 2011 | 2148 | 0.230 |
Why?
|
| Regression Analysis | 12 | 2015 | 6459 | 0.230 |
Why?
|
| Ramipril | 1 | 2003 | 95 | 0.220 |
Why?
|
| Massachusetts | 25 | 2016 | 8662 | 0.220 |
Why?
|
| Logistic Models | 16 | 2015 | 13409 | 0.220 |
Why?
|
| Antirheumatic Agents | 1 | 2013 | 1338 | 0.220 |
Why?
|
| Health Services Accessibility | 11 | 2017 | 5135 | 0.220 |
Why?
|
| Consumer Product Safety | 2 | 2014 | 122 | 0.220 |
Why?
|
| Anticoagulants | 4 | 2008 | 4600 | 0.220 |
Why?
|
| Young Adult | 20 | 2021 | 56429 | 0.220 |
Why?
|
| Policy Making | 3 | 2015 | 554 | 0.220 |
Why?
|
| Total Quality Management | 2 | 2003 | 274 | 0.220 |
Why?
|
| Cohort Studies | 30 | 2018 | 40559 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2020 | 3020 | 0.210 |
Why?
|
| Hospitals | 11 | 2015 | 3954 | 0.210 |
Why?
|
| Rate Setting and Review | 1 | 2002 | 41 | 0.210 |
Why?
|
| Health Priorities | 1 | 2005 | 380 | 0.210 |
Why?
|
| British Columbia | 7 | 2004 | 244 | 0.210 |
Why?
|
| Attitude of Health Personnel | 6 | 2012 | 3841 | 0.210 |
Why?
|
| Diuretics | 1 | 2005 | 591 | 0.210 |
Why?
|
| Blood Transfusion | 3 | 1993 | 1301 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 3 | 2007 | 1070 | 0.200 |
Why?
|
| Community Pharmacy Services | 2 | 2003 | 46 | 0.200 |
Why?
|
| Telephone | 3 | 2010 | 617 | 0.200 |
Why?
|
| Family Practice | 6 | 2013 | 516 | 0.190 |
Why?
|
| Health Services Misuse | 4 | 1996 | 243 | 0.190 |
Why?
|
| Homes for the Aged | 4 | 2010 | 260 | 0.190 |
Why?
|
| Endpoint Determination | 2 | 2014 | 601 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2014 | 7730 | 0.190 |
Why?
|
| Age Factors | 11 | 2014 | 18373 | 0.180 |
Why?
|
| Spironolactone | 1 | 2003 | 382 | 0.180 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 526 | 0.180 |
Why?
|
| Child Health Services | 2 | 2016 | 667 | 0.180 |
Why?
|
| Indoles | 1 | 2008 | 1839 | 0.180 |
Why?
|
| Health Surveys | 5 | 2018 | 4036 | 0.180 |
Why?
|
| Minnesota | 6 | 2000 | 344 | 0.180 |
Why?
|
| Physicians | 6 | 2017 | 4567 | 0.180 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2016 | 1205 | 0.180 |
Why?
|
| Pharmacy Administration | 1 | 1999 | 3 | 0.180 |
Why?
|
| Journalism, Medical | 1 | 2000 | 74 | 0.180 |
Why?
|
| Speech Recognition Software | 2 | 2010 | 72 | 0.180 |
Why?
|
| Government Regulation | 2 | 2014 | 522 | 0.170 |
Why?
|
| Aspirin | 10 | 2001 | 3283 | 0.170 |
Why?
|
| Child | 33 | 2021 | 77709 | 0.170 |
Why?
|
| Patient Care | 1 | 2005 | 640 | 0.170 |
Why?
|
| Prevalence | 11 | 2021 | 15221 | 0.170 |
Why?
|
| Organizational Policy | 3 | 2011 | 429 | 0.170 |
Why?
|
| Medical Staff | 2 | 2004 | 43 | 0.170 |
Why?
|
| Confidence Intervals | 5 | 2010 | 2971 | 0.160 |
Why?
|
| Vulnerable Populations | 3 | 2019 | 686 | 0.160 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 441 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 13 | 2015 | 7282 | 0.160 |
Why?
|
| Pharmacy Service, Hospital | 2 | 1993 | 133 | 0.160 |
Why?
|
| Hyperlipidemias | 3 | 2011 | 789 | 0.160 |
Why?
|
| Eligibility Determination | 4 | 2017 | 403 | 0.160 |
Why?
|
| Evidence-Based Medicine | 3 | 2007 | 3611 | 0.160 |
Why?
|
| Interviews as Topic | 6 | 2007 | 2539 | 0.160 |
Why?
|
| Time Factors | 18 | 2018 | 40075 | 0.150 |
Why?
|
| New England | 7 | 2011 | 1022 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2282 | 0.150 |
Why?
|
| Income | 5 | 2019 | 1913 | 0.150 |
Why?
|
| Chlorofluorocarbons | 1 | 2016 | 12 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 3712 | 0.150 |
Why?
|
| Selection Bias | 2 | 2015 | 371 | 0.150 |
Why?
|
| Retrospective Studies | 29 | 2020 | 77460 | 0.150 |
Why?
|
| Multivariate Analysis | 12 | 2015 | 12244 | 0.140 |
Why?
|
| Missouri | 1 | 2016 | 117 | 0.140 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1998 | 204 | 0.140 |
Why?
|
| South Carolina | 1 | 2016 | 99 | 0.140 |
Why?
|
| Diarrhea, Infantile | 1 | 1996 | 109 | 0.140 |
Why?
|
| Pharmacies | 2 | 2009 | 150 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 4561 | 0.140 |
Why?
|
| Family Health | 2 | 2012 | 1281 | 0.140 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 2575 | 0.140 |
Why?
|
| Specialization | 1 | 2001 | 776 | 0.140 |
Why?
|
| Cardiology Service, Hospital | 1 | 1998 | 246 | 0.140 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 139 | 0.140 |
Why?
|
| Proportional Hazards Models | 7 | 2011 | 12356 | 0.140 |
Why?
|
| Albuterol | 1 | 2016 | 208 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2015 | 11726 | 0.130 |
Why?
|
| Social Desirability | 1 | 2015 | 47 | 0.130 |
Why?
|
| Breast Neoplasms | 7 | 2019 | 20824 | 0.130 |
Why?
|
| Indiana | 3 | 2011 | 92 | 0.130 |
Why?
|
| Health Education | 4 | 2008 | 1056 | 0.130 |
Why?
|
| Postnatal Care | 4 | 2011 | 236 | 0.130 |
Why?
|
| Truth Disclosure | 2 | 2015 | 436 | 0.130 |
Why?
|
| Administrative Personnel | 1 | 2016 | 187 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 9 | 2008 | 7182 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 19905 | 0.120 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 3677 | 0.120 |
Why?
|
| Safety Management | 2 | 2015 | 783 | 0.120 |
Why?
|
| Health Care Surveys | 5 | 2018 | 2453 | 0.120 |
Why?
|
| Michigan | 3 | 2011 | 350 | 0.120 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 299 | 0.120 |
Why?
|
| Pharmacists | 5 | 2003 | 248 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2001 | 1504 | 0.120 |
Why?
|
| Geriatrics | 1 | 1999 | 397 | 0.120 |
Why?
|
| Dextropropoxyphene | 4 | 1993 | 26 | 0.120 |
Why?
|
| Mediastinitis | 1 | 2013 | 48 | 0.120 |
Why?
|
| Anticholesteremic Agents | 2 | 2017 | 979 | 0.120 |
Why?
|
| Child, Preschool | 18 | 2016 | 41005 | 0.120 |
Why?
|
| Algorithms | 2 | 2014 | 13882 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 7914 | 0.120 |
Why?
|
| Residence Characteristics | 4 | 2018 | 2050 | 0.120 |
Why?
|
| Decision Making | 7 | 2018 | 3888 | 0.110 |
Why?
|
| Fluid Therapy | 2 | 1996 | 593 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 818 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 1622 | 0.110 |
Why?
|
| Competitive Medical Plans | 1 | 2013 | 24 | 0.110 |
Why?
|
| Administration, Inhalation | 2 | 2015 | 1105 | 0.110 |
Why?
|
| Hormones | 1 | 1997 | 889 | 0.110 |
Why?
|
| Preventive Medicine | 1 | 2015 | 264 | 0.110 |
Why?
|
| Hospital Charges | 1 | 2015 | 362 | 0.110 |
Why?
|
| Drugs, Generic | 1 | 2017 | 421 | 0.110 |
Why?
|
| Length of Stay | 6 | 2007 | 6311 | 0.110 |
Why?
|
| Costs and Cost Analysis | 5 | 2007 | 1680 | 0.110 |
Why?
|
| Medicine | 1 | 2001 | 946 | 0.110 |
Why?
|
| Odds Ratio | 6 | 2021 | 9849 | 0.110 |
Why?
|
| Communication | 4 | 2018 | 3750 | 0.110 |
Why?
|
| Social Security | 1 | 2012 | 101 | 0.110 |
Why?
|
| Reye Syndrome | 1 | 1992 | 28 | 0.110 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 3086 | 0.110 |
Why?
|
| Compensation and Redress | 1 | 2012 | 71 | 0.110 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1996 | 397 | 0.100 |
Why?
|
| Substance-Related Disorders | 3 | 2004 | 4257 | 0.100 |
Why?
|
| Colorectal Neoplasms | 4 | 2016 | 6773 | 0.100 |
Why?
|
| Peer Review, Research | 1 | 1995 | 329 | 0.100 |
Why?
|
| Epidemiologic Studies | 1 | 2015 | 676 | 0.100 |
Why?
|
| Physicians, Family | 3 | 2004 | 345 | 0.100 |
Why?
|
| Hospital Costs | 2 | 2015 | 985 | 0.100 |
Why?
|
| Emergency Medical Services | 2 | 2016 | 1917 | 0.100 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2016 | 1209 | 0.100 |
Why?
|
| Sex Factors | 9 | 2014 | 10400 | 0.100 |
Why?
|
| Prepaid Health Plans | 1 | 2010 | 10 | 0.100 |
Why?
|
| Diabetes Complications | 2 | 2017 | 1359 | 0.100 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 4933 | 0.100 |
Why?
|
| Hospitals, Maternity | 1 | 2011 | 42 | 0.100 |
Why?
|
| Hospitalists | 2 | 2007 | 305 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2009 | 3070 | 0.090 |
Why?
|
| Canada | 2 | 2008 | 2065 | 0.090 |
Why?
|
| Legislation, Medical | 1 | 2011 | 100 | 0.090 |
Why?
|
| International Classification of Diseases | 2 | 2014 | 867 | 0.090 |
Why?
|
| Medicare Part B | 2 | 2001 | 108 | 0.090 |
Why?
|
| Comorbidity | 7 | 2014 | 10388 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2006 | 5035 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 1996 | 865 | 0.090 |
Why?
|
| Risk Assessment | 7 | 2010 | 23336 | 0.090 |
Why?
|
| Antimanic Agents | 1 | 2014 | 522 | 0.090 |
Why?
|
| Infection Control | 2 | 2015 | 965 | 0.090 |
Why?
|
| Teaching | 1 | 1998 | 1174 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2012 | 281 | 0.090 |
Why?
|
| Diffusion of Innovation | 2 | 2012 | 725 | 0.090 |
Why?
|
| Population Surveillance | 3 | 2018 | 2616 | 0.090 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 2419 | 0.090 |
Why?
|
| Patient Admission | 3 | 2013 | 1380 | 0.090 |
Why?
|
| Oxycodone | 2 | 2008 | 153 | 0.090 |
Why?
|
| Child Behavior | 1 | 2015 | 839 | 0.090 |
Why?
|
| Survivors | 3 | 2011 | 2291 | 0.090 |
Why?
|
| Insurance Benefits | 1 | 2011 | 183 | 0.080 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 25039 | 0.080 |
Why?
|
| Time | 2 | 2018 | 542 | 0.080 |
Why?
|
| Databases as Topic | 2 | 2009 | 475 | 0.080 |
Why?
|
| Preventive Health Services | 2 | 2011 | 575 | 0.080 |
Why?
|
| Breast | 1 | 1998 | 1970 | 0.080 |
Why?
|
| Social Class | 3 | 2013 | 1997 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1997 | 3480 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 204 | 0.080 |
Why?
|
| Attitude to Health | 3 | 2007 | 2052 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 3 | 2015 | 1162 | 0.080 |
Why?
|
| Coronary Disease | 2 | 2001 | 6077 | 0.080 |
Why?
|
| Respiratory Tract Infections | 2 | 2008 | 961 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 2 | 2006 | 119 | 0.080 |
Why?
|
| Developing Countries | 2 | 2001 | 2815 | 0.080 |
Why?
|
| Lidocaine | 3 | 2001 | 544 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2001 | 146 | 0.080 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 783 | 0.080 |
Why?
|
| Publishing | 1 | 2015 | 833 | 0.080 |
Why?
|
| Postal Service | 1 | 2008 | 96 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 738 | 0.080 |
Why?
|
| Mammography | 2 | 2018 | 2475 | 0.080 |
Why?
|
| Perphenazine | 1 | 2007 | 34 | 0.080 |
Why?
|
| Insurance, Hospitalization | 1 | 2007 | 30 | 0.080 |
Why?
|
| Occult Blood | 3 | 2016 | 176 | 0.070 |
Why?
|
| Marketing of Health Services | 1 | 2008 | 153 | 0.070 |
Why?
|
| Health Literacy | 1 | 2013 | 414 | 0.070 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 633 | 0.070 |
Why?
|
| Boston | 6 | 2004 | 9312 | 0.070 |
Why?
|
| Cardiology | 1 | 1998 | 1668 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2013 | 802 | 0.070 |
Why?
|
| Washington | 2 | 2004 | 313 | 0.070 |
Why?
|
| Sulfamethoxazole | 1 | 2006 | 53 | 0.070 |
Why?
|
| Breast Feeding | 3 | 2004 | 1338 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2001 | 789 | 0.070 |
Why?
|
| Carcinoma | 1 | 1998 | 2375 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 1831 | 0.070 |
Why?
|
| Fibrinolytic Agents | 4 | 2000 | 2158 | 0.070 |
Why?
|
| Antidiarrheals | 2 | 1996 | 45 | 0.070 |
Why?
|
| Hospitals, Teaching | 4 | 2002 | 1180 | 0.070 |
Why?
|
| Depression, Postpartum | 1 | 2011 | 340 | 0.070 |
Why?
|
| Metronidazole | 2 | 2006 | 217 | 0.070 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 941 | 0.070 |
Why?
|
| Fluconazole | 1 | 2006 | 146 | 0.070 |
Why?
|
| Chlorpromazine | 1 | 2005 | 111 | 0.070 |
Why?
|
| Infant | 10 | 2015 | 35134 | 0.070 |
Why?
|
| Online Systems | 1 | 2006 | 184 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2006 | 1364 | 0.060 |
Why?
|
| Demography | 2 | 2006 | 1655 | 0.060 |
Why?
|
| Computer User Training | 1 | 2004 | 19 | 0.060 |
Why?
|
| Therapeutic Equivalency | 2 | 2002 | 141 | 0.060 |
Why?
|
| Quality Improvement | 3 | 2015 | 3749 | 0.060 |
Why?
|
| Feedback, Psychological | 1 | 2005 | 97 | 0.060 |
Why?
|
| Psychometrics | 2 | 2008 | 3003 | 0.060 |
Why?
|
| Episode of Care | 1 | 2005 | 126 | 0.060 |
Why?
|
| Crisis Intervention | 1 | 2005 | 105 | 0.060 |
Why?
|
| Oregon | 1 | 2004 | 140 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 1 | 2008 | 862 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2005 | 296 | 0.060 |
Why?
|
| Patient Participation | 3 | 2010 | 1457 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1540 | 0.060 |
Why?
|
| Attitude to Computers | 1 | 2005 | 202 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 2288 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2009 | 1000 | 0.060 |
Why?
|
| Patient Discharge | 4 | 2007 | 3318 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2009 | 899 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2013 | 5321 | 0.060 |
Why?
|
| Haloperidol | 1 | 2005 | 397 | 0.060 |
Why?
|
| Sampling Studies | 2 | 2008 | 623 | 0.060 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 71 | 0.060 |
Why?
|
| Morale | 1 | 1983 | 12 | 0.060 |
Why?
|
| Follow-Up Studies | 11 | 2012 | 39052 | 0.060 |
Why?
|
| Hospitals, Community | 2 | 1998 | 347 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2002 | 10252 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2011 | 1092 | 0.060 |
Why?
|
| Treatment Outcome | 10 | 2018 | 63107 | 0.060 |
Why?
|
| Fever | 2 | 2010 | 1616 | 0.060 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2003 | 43 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6539 | 0.060 |
Why?
|
| Risperidone | 1 | 2005 | 383 | 0.050 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 352 | 0.050 |
Why?
|
| Physician-Patient Relations | 4 | 2008 | 3229 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2015 | 25628 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2007 | 3922 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2018 | 3444 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 1410 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2006 | 545 | 0.050 |
Why?
|
| Insurance, Medigap | 1 | 2001 | 19 | 0.050 |
Why?
|
| Data Collection | 5 | 2008 | 3339 | 0.050 |
Why?
|
| Pharmacoepidemiology | 2 | 2003 | 323 | 0.050 |
Why?
|
| Retirement | 1 | 1983 | 216 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2006 | 1460 | 0.050 |
Why?
|
| Least-Squares Analysis | 2 | 1993 | 379 | 0.050 |
Why?
|
| Infant Care | 1 | 2002 | 183 | 0.050 |
Why?
|
| Risk | 2 | 2007 | 9688 | 0.050 |
Why?
|
| Interprofessional Relations | 3 | 1998 | 1011 | 0.050 |
Why?
|
| Peptic Ulcer | 2 | 2003 | 223 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 269 | 0.050 |
Why?
|
| State Government | 1 | 2004 | 372 | 0.050 |
Why?
|
| Geriatric Assessment | 2 | 2007 | 1372 | 0.050 |
Why?
|
| Mastectomy | 2 | 2000 | 1793 | 0.050 |
Why?
|
| Drugs, Essential | 1 | 2001 | 73 | 0.050 |
Why?
|
| Cost Savings | 3 | 2004 | 925 | 0.050 |
Why?
|
| Colonoscopy | 3 | 2016 | 1367 | 0.050 |
Why?
|
| Health | 1 | 1983 | 394 | 0.040 |
Why?
|
| Outpatients | 1 | 2007 | 1487 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2003 | 465 | 0.040 |
Why?
|
| Incidence | 5 | 2010 | 20952 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2006 | 987 | 0.040 |
Why?
|
| Nicardipine | 1 | 1999 | 60 | 0.040 |
Why?
|
| Alendronate | 1 | 2000 | 171 | 0.040 |
Why?
|
| Diarrhea | 2 | 1996 | 1348 | 0.040 |
Why?
|
| Risk Factors | 11 | 2021 | 72296 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2001 | 1677 | 0.040 |
Why?
|
| Pain | 2 | 2006 | 4988 | 0.040 |
Why?
|
| Diltiazem | 1 | 1999 | 133 | 0.040 |
Why?
|
| Nifedipine | 1 | 1999 | 227 | 0.040 |
Why?
|
| Verapamil | 1 | 1999 | 244 | 0.040 |
Why?
|
| Povidone | 1 | 1978 | 33 | 0.040 |
Why?
|
| Procaine | 1 | 1978 | 60 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2205 | 0.040 |
Why?
|
| Manitoba | 1 | 2017 | 23 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 6489 | 0.040 |
Why?
|
| Pravastatin | 1 | 2000 | 395 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2002 | 607 | 0.040 |
Why?
|
| Industry | 3 | 1995 | 365 | 0.040 |
Why?
|
| Vaccination | 1 | 2010 | 3279 | 0.040 |
Why?
|
| Kenya | 2 | 1996 | 685 | 0.040 |
Why?
|
| Aftercare | 1 | 2003 | 870 | 0.040 |
Why?
|
| Horses | 1 | 2018 | 304 | 0.040 |
Why?
|
| Television | 1 | 2000 | 409 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1999 | 392 | 0.040 |
Why?
|
| Education, Pharmacy | 1 | 1996 | 35 | 0.040 |
Why?
|
| Sigmoid Neoplasms | 1 | 1976 | 51 | 0.030 |
Why?
|
| Biopsy | 2 | 2019 | 6755 | 0.030 |
Why?
|
| Neoplasms | 3 | 2017 | 21696 | 0.030 |
Why?
|
| Employment | 1 | 1983 | 1132 | 0.030 |
Why?
|
| Soil | 1 | 2016 | 106 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2001 | 693 | 0.030 |
Why?
|
| Persuasive Communication | 1 | 1996 | 59 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2000 | 780 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2008 | 2020 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1980 | 604 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1999 | 657 | 0.030 |
Why?
|
| Mesentery | 1 | 1976 | 205 | 0.030 |
Why?
|
| Reference Values | 3 | 2010 | 4982 | 0.030 |
Why?
|
| Diagnosis-Related Groups | 1 | 1997 | 455 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 1999 | 517 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 2 | 2003 | 782 | 0.030 |
Why?
|
| Home Infusion Therapy | 1 | 1995 | 19 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2000 | 570 | 0.030 |
Why?
|
| Plants, Toxic | 1 | 1995 | 76 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2000 | 544 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2009 | 3914 | 0.030 |
Why?
|
| Cephalexin | 2 | 1986 | 37 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2011 | 8551 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 1170 | 0.030 |
Why?
|
| Motivation | 3 | 1996 | 1971 | 0.030 |
Why?
|
| Rural Health | 1 | 1996 | 305 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2001 | 850 | 0.030 |
Why?
|
| Arm | 1 | 1978 | 589 | 0.030 |
Why?
|
| Axilla | 1 | 1997 | 597 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1976 | 292 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 1997 | 353 | 0.030 |
Why?
|
| Patient Selection | 3 | 2002 | 4216 | 0.030 |
Why?
|
| Disclosure | 1 | 2000 | 736 | 0.030 |
Why?
|
| Critical Pathways | 1 | 1998 | 476 | 0.030 |
Why?
|
| Tolmetin | 1 | 1993 | 23 | 0.030 |
Why?
|
| Urban Health | 1 | 1996 | 547 | 0.030 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1993 | 60 | 0.030 |
Why?
|
| Pacific Islands | 1 | 2013 | 50 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2006 | 3461 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2008 | 5101 | 0.030 |
Why?
|
| Child Welfare | 2 | 2010 | 523 | 0.030 |
Why?
|
| Economic Recession | 1 | 2014 | 78 | 0.030 |
Why?
|
| Informed Consent | 1 | 2000 | 995 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 1980 | 806 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2002 | 1775 | 0.030 |
Why?
|
| Tobramycin | 1 | 1993 | 69 | 0.030 |
Why?
|
| Inservice Training | 1 | 1996 | 392 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 11031 | 0.030 |
Why?
|
| Education, Medical | 1 | 1985 | 1722 | 0.030 |
Why?
|
| Information Services | 1 | 1994 | 244 | 0.030 |
Why?
|
| Prospective Payment System | 1 | 2013 | 133 | 0.030 |
Why?
|
| Prejudice | 1 | 1997 | 570 | 0.030 |
Why?
|
| Disease Management | 1 | 2003 | 2460 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 1993 | 160 | 0.030 |
Why?
|
| Factor VIII | 1 | 1995 | 347 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 986 | 0.030 |
Why?
|
| Patient Transfer | 1 | 1999 | 762 | 0.030 |
Why?
|
| Consumer Organizations | 1 | 1992 | 10 | 0.030 |
Why?
|
| California | 1 | 2016 | 1402 | 0.030 |
Why?
|
| Norway | 1 | 2013 | 448 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2887 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 1998 | 1262 | 0.030 |
Why?
|
| Clindamycin | 2 | 1989 | 139 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 392 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 609 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1995 | 351 | 0.020 |
Why?
|
| Anxiety | 1 | 2006 | 4293 | 0.020 |
Why?
|
| Hospital Mortality | 2 | 2002 | 5316 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 2 | 2002 | 87 | 0.020 |
Why?
|
| Internal Medicine | 1 | 1998 | 1009 | 0.020 |
Why?
|
| Feedback | 2 | 2000 | 795 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2018 | 3589 | 0.020 |
Why?
|
| Community Health Services | 1 | 1996 | 650 | 0.020 |
Why?
|
| Office Visits | 2 | 2005 | 598 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2000 | 1579 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 2232 | 0.020 |
Why?
|
| Public Policy | 1 | 1995 | 572 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1151 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1980 | 1332 | 0.020 |
Why?
|
| Probability | 2 | 2008 | 2506 | 0.020 |
Why?
|
| Nursing Staff | 1 | 1991 | 129 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2013 | 211 | 0.020 |
Why?
|
| Politics | 1 | 1997 | 791 | 0.020 |
Why?
|
| Premedication | 1 | 1990 | 258 | 0.020 |
Why?
|
| Blood Banks | 1 | 1990 | 111 | 0.020 |
Why?
|
| Continuity of Patient Care | 2 | 2011 | 1049 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2010 | 104 | 0.020 |
Why?
|
| Teaching Materials | 1 | 1990 | 86 | 0.020 |
Why?
|
| Deinstitutionalization | 1 | 1989 | 21 | 0.020 |
Why?
|
| Self Care | 1 | 1995 | 786 | 0.020 |
Why?
|
| Intermediate Care Facilities | 1 | 1988 | 9 | 0.020 |
Why?
|
| Nonodontogenic Cysts | 1 | 1968 | 4 | 0.020 |
Why?
|
| Referral and Consultation | 2 | 2000 | 3531 | 0.020 |
Why?
|
| Analgesia | 1 | 1993 | 461 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2297 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2010 | 221 | 0.020 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 1246 | 0.020 |
Why?
|
| Maxillary Diseases | 1 | 1968 | 51 | 0.020 |
Why?
|
| Hyperglycemia | 2 | 2010 | 1373 | 0.020 |
Why?
|
| Biomedical Research | 3 | 2000 | 3309 | 0.020 |
Why?
|
| Peer Group | 2 | 2005 | 635 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2902 | 0.020 |
Why?
|
| Postmenopause | 1 | 1997 | 2460 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2018 | 53290 | 0.020 |
Why?
|
| Enema | 1 | 2008 | 141 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2008 | 156 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2010 | 578 | 0.020 |
Why?
|
| Comprehension | 1 | 2013 | 610 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 574 | 0.020 |
Why?
|
| Organizational Innovation | 2 | 2004 | 559 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2011 | 21748 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2006 | 47 | 0.020 |
Why?
|
| Analgesics | 1 | 1993 | 1040 | 0.020 |
Why?
|
| Arkansas | 1 | 1986 | 52 | 0.020 |
Why?
|
| Stroke | 2 | 2006 | 9981 | 0.020 |
Why?
|
| Vermont | 1 | 1986 | 85 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 788 | 0.020 |
Why?
|
| Health Behavior | 1 | 2018 | 2635 | 0.020 |
Why?
|
| Blood Donors | 1 | 1988 | 355 | 0.020 |
Why?
|
| District of Columbia | 1 | 1986 | 157 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 4639 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1999 | 6442 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15078 | 0.020 |
Why?
|
| Korea | 1 | 2005 | 99 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2007 | 513 | 0.020 |
Why?
|
| Bacteremia | 1 | 2012 | 963 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1997 | 3476 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 1256 | 0.020 |
Why?
|
| Patient Care Planning | 2 | 2007 | 921 | 0.020 |
Why?
|
| Professional Competence | 1 | 1989 | 447 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2008 | 511 | 0.020 |
Why?
|
| General Surgery | 2 | 2000 | 1636 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2005 | 5791 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 968 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 1781 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 451 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 1768 | 0.020 |
Why?
|
| Methadone | 1 | 2006 | 306 | 0.020 |
Why?
|
| Papaverine | 1 | 1983 | 46 | 0.010 |
Why?
|
| Gastric Acid | 1 | 2003 | 104 | 0.010 |
Why?
|
| Forecasting | 1 | 1993 | 2951 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2008 | 1794 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 661 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1342 | 0.010 |
Why?
|
| Infant Food | 1 | 2003 | 141 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 2428 | 0.010 |
Why?
|
| Benzene | 2 | 1953 | 100 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1993 | 2760 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 984 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1988 | 971 | 0.010 |
Why?
|
| Patients | 1 | 1989 | 900 | 0.010 |
Why?
|
| Group Practice, Prepaid | 1 | 2001 | 14 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 657 | 0.010 |
Why?
|
| Accidental Falls | 1 | 2010 | 1062 | 0.010 |
Why?
|
| Family | 1 | 2013 | 3147 | 0.010 |
Why?
|
| Insulin | 2 | 2007 | 6582 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1980 | 5181 | 0.010 |
Why?
|
| Poisoning | 2 | 1953 | 249 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1877 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1990 | 6366 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2009 | 1099 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 1210 | 0.010 |
Why?
|
| National Health Programs | 1 | 2004 | 445 | 0.010 |
Why?
|
| Phototherapy | 1 | 2004 | 377 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 347 | 0.010 |
Why?
|
| Computers | 1 | 1982 | 612 | 0.010 |
Why?
|
| Community Networks | 1 | 2001 | 203 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1980 | 382 | 0.010 |
Why?
|
| Steroids | 1 | 2004 | 930 | 0.010 |
Why?
|
| Prognosis | 3 | 2011 | 29060 | 0.010 |
Why?
|
| Hospital Bed Capacity | 1 | 2000 | 215 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2004 | 970 | 0.010 |
Why?
|
| Stress, Psychological | 2 | 1991 | 4245 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1983 | 976 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8642 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1978 | 5692 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1983 | 643 | 0.010 |
Why?
|
| Patient Readmission | 2 | 2002 | 3116 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 490 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 499 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15535 | 0.010 |
Why?
|
| Inpatients | 1 | 1989 | 2518 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 865 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2003 | 455 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2000 | 402 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 674 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1956 | 43 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12788 | 0.010 |
Why?
|
| Panniculitis, Nodular Nonsuppurative | 1 | 1976 | 7 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4671 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1978 | 667 | 0.010 |
Why?
|
| Indonesia | 1 | 1996 | 119 | 0.010 |
Why?
|
| Occupational Health | 2 | 1953 | 808 | 0.010 |
Why?
|
| Home Care Services | 1 | 2002 | 606 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3047 | 0.010 |
Why?
|
| Purpura | 1 | 1956 | 122 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3154 | 0.010 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1956 | 131 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2000 | 956 | 0.010 |
Why?
|
| Psychiatry | 1 | 2007 | 1695 | 0.010 |
Why?
|
| Workload | 1 | 2000 | 849 | 0.010 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 1994 | 92 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 10943 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2000 | 15160 | 0.010 |
Why?
|
| Education, Nursing, Continuing | 1 | 1992 | 75 | 0.010 |
Why?
|
| Geriatric Psychiatry | 1 | 1992 | 70 | 0.010 |
Why?
|
| Education, Continuing | 1 | 1992 | 112 | 0.010 |
Why?
|
| Microcomputers | 1 | 1992 | 147 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 5953 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1990 | 36 | 0.010 |
Why?
|
| Mental Processes | 1 | 1992 | 249 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 7147 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1991 | 321 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2789 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 12721 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29144 | 0.010 |
Why?
|
| Behavior Control | 1 | 1988 | 45 | 0.010 |
Why?
|
| Parents | 1 | 2002 | 3405 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1956 | 1178 | 0.010 |
Why?
|
| Behavioral Research | 1 | 1988 | 54 | 0.010 |
Why?
|
| Mentally Ill Persons | 1 | 1988 | 126 | 0.000 |
Why?
|
| Cefazolin | 1 | 1988 | 96 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 1681 | 0.000 |
Why?
|
| Information Systems | 1 | 1989 | 410 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1994 | 1547 | 0.000 |
Why?
|
| Facial Injuries | 1 | 1968 | 183 | 0.000 |
Why?
|
| Marriage | 1 | 1988 | 339 | 0.000 |
Why?
|
| Professional Practice | 1 | 1989 | 326 | 0.000 |
Why?
|
| Animals | 1 | 2018 | 168768 | 0.000 |
Why?
|
| Placebos | 1 | 1989 | 1676 | 0.000 |
Why?
|
| Documentation | 1 | 1990 | 871 | 0.000 |
Why?
|
| Registries | 1 | 1999 | 8091 | 0.000 |
Why?
|
| Research | 1 | 1992 | 1999 | 0.000 |
Why?
|
| Cesarean Section | 1 | 1990 | 1365 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1976 | 12961 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1401 | 0.000 |
Why?
|
| Sexual Behavior | 1 | 1988 | 2055 | 0.000 |
Why?
|
| Athletic Injuries | 1 | 1968 | 1154 | 0.000 |
Why?
|
| Software | 1 | 1992 | 4441 | 0.000 |
Why?
|
| Radiography | 1 | 1968 | 7023 | 0.000 |
Why?
|
| Inflammation | 1 | 1976 | 10637 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1988 | 8319 | 0.000 |
Why?
|
| Quality of Life | 1 | 1995 | 12802 | 0.000 |
Why?
|